Shi, Y.(2017). First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): A phase 3, open-label, randomized study. Annals of Oncology, 28(10), 2443-2450. doi:10.1093/annonc/mdx359

Shi, Y.K. "First-line Icotinib Versus Cisplatin/pemetrexed Plus Pemetrexed Maintenance Therapy for Patients With AdvancedEGFR Mutation-positive Lung Adenocarcinoma (CONVINCE): A Phase 3, Open-label, Randomized Study". Annals of Oncology, 28.10 ( 2017 ): 2443-2450.